SC
GILD icon

Schubert & Co’s Gilead Sciences GILD Stock Holding History

Schubert & Co’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-311
Closed -$25.8K – 627
2023
Q1 		$25.8K Sell
311
-8
-3% -$663 0.02% 107
2022
Q4 		$27.4K Buy
319
+62
+24% +$4.91K 0.03% 92
2022
Q3 		$16K Buy
257
+100
+64% +$6.31K 0.02% 123
2022
Q2 		$10K Buy
157
+105
+202% +$6.5K 0.01% 182
2022
Q1 		$3K Buy
52
+20
+63% +$1.28K ﹤0.01% 273
2021
Q4 		$2K Buy
+32
New +$2.2K ﹤0.01% 368

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Schubert & Co's GILD Position: Q2 2023 in Review

Schubert & Co sold out of Gilead Sciences (GILD) in Q2 2023, closing a stake of 311 shares — an estimated $25.8K sold.

Schubert & Co first reported a position in GILD in Q4 2021 and held it in 6 quarters. The position peaked at $27.4K in Q4 2022. 1,701 funds tracked by Wall St. Rank hold GILD as of Q2 2023.

  • Schubert & Co reported no remaining Gilead Sciences position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 311 Gilead Sciences shares in Q2 2023, an estimated $25.8K.
  • Schubert & Co first reported a position in Gilead Sciences in Q4 2021 and held it in 6 quarters.
  • Schubert & Co's Gilead Sciences position peaked at $27.4K in Q4 2022.
  • 1,701 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.